Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up – Still a Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE) gapped up before the market opened on Tuesday . The stock had previously closed at $22.39, but opened at $24.52. Maze Therapeutics shares last traded at $27.8850, with a volume of 615,856 shares traded.

Analyst Ratings Changes

A number of research firms recently issued reports on MAZE. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. BTIG Research reiterated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, August 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Trading Up 24.0%

The business’s 50 day simple moving average is $27.24 and its 200 day simple moving average is $29.42. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -10.96 and a beta of 2.17. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.76). On average, research analysts expect that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Insider Transactions at Maze Therapeutics

In related news, CEO Jason V. Coloma sold 11,411 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $296,800.11. Following the completion of the sale, the chief executive officer owned 27,362 shares of the company’s stock, valued at $711,685.62. This represents a 29.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Harold Bernstein sold 9,705 shares of Maze Therapeutics stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $26.22, for a total transaction of $254,465.10. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 191,459 shares of company stock worth $5,263,539 over the last ninety days. Corporate insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Maze Therapeutics

Institutional investors have recently modified their holdings of the business. Frazier Life Sciences Management L.P. lifted its position in shares of Maze Therapeutics by 10.2% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after buying an additional 465,641 shares during the last quarter. TRV GP IV LLC bought a new position in Maze Therapeutics in the second quarter valued at about $133,502,907. ARCH Venture Management LLC acquired a new position in Maze Therapeutics during the second quarter worth about $122,983,582. BlackRock Inc. bought a new position in shares of Maze Therapeutics in the second quarter worth about $104,525,000. Finally, Jupiter Topco LLC bought a new position in shares of Maze Therapeutics in the second quarter worth about $101,764,000.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.